Extended Data Fig. 9: Combination therapy targeting GLS and the SSP suppresses breast cancer growth.
From: The unique catalytic properties of PSAT1 mediate metabolic adaptation to glutamine blockade
a, Body weight measurement of tumor-bearing mice in the indicated treatment groups. n = 6 (MDA-MB-231) or n = 7 (BT-549) biological replicates, error bars represent SEM. b, Growth of control and PSAT1-knockout MDA-MB-231 orthotopic breast tumor xenografts in NU/J mice administered the indicated treatments (left panel), and body weight measurements of tumor-bearing mice under the indicated treatment (right panel). Data are presented as mean values ± SEM, n = 3 biological replicates. Two-tailed unpaired t-test. ** P ≤ 0.01. c, Western blot analysis of PSAT1 in cultured cells and orthotopic breast tumor xenografts harvested from untreated or CB-839 treated mice. PSAT1, phosphoserine aminotransferase 1.
